Altimmune, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2020 Annual Meeting of Stockholders held by Altimmune, Inc. on September 24, 2020. The record date for the meeting was August 20, 2020, with 32,911,833 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
A total of 27,114,999 shares were present or represented by proxy, representing 82.38% of issued and outstanding shares, establishing a quorum. The voting results for the four proposals were as follows:
- Proposal 1 (Election of Directors): All eight nominees were elected. Notable withhold votes included John M. Gill (4,865,619) and Wayne Pisano (1,905,686), while other directors received withhold votes ranging from approximately 1.14 million to 1.17 million. Broker non-votes totaled 9,742,550 for all director nominees.
- Proposal 2 (Ratification of Auditors): The appointment of Ernst & Young LLP was ratified with 27,037,507 votes For, 31,065 Against, and 46,427 Abstain.
- Proposal 3 (Say-on-Pay): The advisory vote on executive compensation passed with 15,939,791 votes For, 1,307,889 Against, and 124,769 Abstain. Broker non-votes totaled 9,742,550.
- Proposal 4 (Adjournment Authorization): The proposal to authorize adjournment to solicit additional proxies passed with 21,063,670 votes For, 5,742,056 Against, and 309,273 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific reasons for the higher number of "Withhold" votes for directors John M. Gill and Wayne Pisano compared to other nominees.
- Confirm the total number of broker non-votes (9,742,550) and their impact on the quorum and voting thresholds.
- Review the full Proxy Statement for details on the executive compensation package approved in Proposal 3.
- Check subsequent filings to determine if the adjournment authority granted in Proposal 4 was utilized.